Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody placulumab, and positive results from the phase 3 studies of remibrutinib.

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Dietary counseling is an effective strategy for managing and preventing nutritional imbalances in pediatric patients with non–IgE-mediated gastrointestinal food allergies, a study shows.

The use of ketamine, midazolam, lorazepam, droperidol, and haloperidol was also assessed. Children who interacted with ...

Vestibular therapy is feasible and may alleviate dizziness symptoms among patients in the emergency department, a pilot study finds.

Implementation of the ERAS program delivers better patient outcomes, achieves shorter lengths of stay, and saves money.

Chewing gum contains plant-based or synthetic plastic polymers, making it a potential source of microplastics; however, the ...

The prevalence of cerebral small vessel disease nearly doubled over 7.5 years in neurologically asymptomatic patients with ...

Same-day discharge after joint replacement surgery is feasible in patients with a history of atrial fibrillation (AF), ...

Discussions at the Advanced Technologies & Treatments for Diabetes meeting covered CGM use in non–insulin-treated people with ...

Inotuzumab ozogamicin is safe and effective in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia, ...